KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $312,108 | +7.0% | 32,410 | 0.0% | 0.00% | – |
| Q2 2023 | $291,690 | +44.4% | 32,410 | +26.1% | 0.00% | – |
| Q1 2023 | $202,002 | +16.3% | 25,700 | 0.0% | 0.00% | – |
| Q4 2022 | $173,732 | -29.9% | 25,700 | +50.6% | 0.00% | – |
| Q3 2022 | $248,000 | +66.4% | 17,064 | +13.0% | 0.00% | – |
| Q2 2022 | $149,000 | -2.6% | 15,100 | +45.2% | 0.00% | – |
| Q1 2022 | $153,000 | -5.0% | 10,400 | -14.8% | 0.00% | – |
| Q4 2021 | $161,000 | -24.4% | 12,200 | 0.0% | 0.00% | – |
| Q3 2021 | $213,000 | -27.1% | 12,200 | 0.0% | 0.00% | – |
| Q2 2021 | $292,000 | -18.2% | 12,200 | -35.1% | 0.00% | – |
| Q4 2020 | $357,000 | +44.0% | 18,800 | -4.6% | 0.00% | – |
| Q3 2020 | $248,000 | +4.2% | 19,700 | 0.0% | 0.00% | – |
| Q2 2020 | $238,000 | +153.2% | 19,700 | +60.2% | 0.00% | – |
| Q1 2020 | $94,000 | -47.8% | 12,300 | +21.8% | 0.00% | – |
| Q4 2019 | $180,000 | +53.8% | 10,100 | 0.0% | 0.00% | – |
| Q3 2019 | $117,000 | – | 10,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $38,088,000 | 25.57% |
| VHCP Management III, LLC | 637,884 | $14,129,000 | 6.60% |
| Vivo Capital, LLC | 1,359,149 | $30,105,000 | 2.82% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $8,611,000 | 2.78% |
| VHCP Management II, LLC | 376,889 | $8,348,000 | 2.63% |
| Samsara BioCapital, LLC | 118,500 | $2,625,000 | 1.73% |
| ACUTA CAPITAL PARTNERS, LLC | 213,000 | $4,718,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 187,599 | $4,165,000 | 1.54% |
| Ghost Tree Capital, LLC | 300,000 | $6,645,000 | 1.38% |
| Eventide Asset Management | 1,500,000 | $33,225,000 | 1.01% |